Integrated Report

Overview

The report details Sumitomo Pharma Group's strategic transition under the Mid-term Business Plan 2027 to address the loss of exclusivity for LATUDA® and drive renewed growth through three core products. The company focuses on expanding its pipelines in psychiatry, neurology, oncology, and regenerative medicine, alongside organizational restructuring in North America. Additionally, Sumitomo Pharma enhanced its environmental commitments by committing to the Science Based Targets initiative and setting a target to reduce Scope 1 and 2 emissions by 42% by fiscal 2030.

Document

Report type: Integrated Report
Class: Embedded
Scope: Full report
Fiscal year: 2022-2023
Period: 1 April 2022 – 31 March 2023
Publication date: 1 October 2023
Language: English
Pages
File size
Restatement: Disclosed

Standards

GRI
SASB
TCFD
ISSB
ESRS
Integrated Reporting Framework
GHG Protocol
EU Taxonomy
CDP
Other

Commitments

UN Global Compact
UN Guiding Principles
Science Based Targets initiative

Ratings

GRI level
SBTi status

Materiality

Assessment
Basis
Matrix

Assurance

Provider
Scope
Statement included
Metrics assured

Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services